STOCK WATCH

A CURE for cancer may have come a step closer for Midatech Pharma.

The small drugs company today announced positive results from its latest trial of MTD201, used to cure carcinoid cancer, which affects the hormone system, and acromegaly, where the body produces too much growth hormone.

The trial suggested the product was better than any on sale. The market for this type of treatment is worth around £1.5bn per year. Shares jumped 19.2pc, or 5p, to 31p.